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ABSTRACT
Advancements in technology have made possible the development of highly
personalized and efficacious medicines. Various forms of immunotherapy have
demonstrated clinical utility in the treatment of blood-based cancers (e.g., leukemia,
lymphoma, etc.). Cells in the tumor microenvironment (TME) of solid tumors can
suppress the immune response of T cells, therefore hindering the efficacy of T-cell
immunotherapies. Consequently, a growing number of studies are investigating
methods of modulating the TME for improving immunotherapeutic outcomes in this
context. Myeloid-derived suppressor cells (MDSCs) are one such cell responsible for
diminishing the activity of immune cells by secreting immunosuppressive cytokines.
Recent studies show that the glycoprotein, CD38, and Wnt-pathway triggering protein,
β-catenin, are differentially expressed in MDSC populations of murine lung and liver
metastases, respectively. MDSCs, chemically differentiated from the PBMCs of healthy
human donors (hMDSCs) can be treated with small molecule inhibitors for validating
the immunomodulatory roles of these targets. Successful candidates from these studies
can be further evaluated in silico for predicting their pharmacokinetic characteristics,
specificity in vivo, and most likely modes for target binding.
Chapter 1 will describe the current state of cancer and the efficacy of its treatment
with immunotherapy. Immunosuppressive cell types and current theories for their
modulation by small molecules and biologics are also introduced. Finally, “omics”
approaches for identifying pharmacologic targets in the TME and the preclinical models
typically used for their translation and validation are discussed.

In Chapter 2 of this thesis, the cytotoxic ranges of synthetic and flavonoid CD38
inhibitors are determined for hMDSCs and autologous T cells. Their influence on
hMDSC production of key immunomodulatory cytokines is also evaluated,
demonstrating the utility of 78c for decreasing the production of immunosuppressive
IL-10, CCL17, and MMP7 while inducing release of CCL4 and IL-1β. Lastly, various
in silico analyses are utilized to predict protein-ligand interactions, pharmacokinetic
characteristics, and in vivo specificity of the tested CD38 inhibitors. Based on the data
from these experiments, synthetic CD38 inhibitor, 78c, represents a promising candidate
for further evaluation of its immunomodulatory potential of in vivo TMEs.
Similarly, Chapter 3 involves the determination of cytotoxic ranges for various
inhibitors of the Wnt/β-catenin pathway, each with unique mechanisms of intervention.
With reference to these ranges, test compounds were again evaluated for their influence
on key immunomodulatory cytokines in hMDSCs where ICRT14 diminished CCL17
and IL-1β while increasing CCL4. When assessed for their ability to decrease IL-10,
FH535 was the only Wnt/β-catenin inhibitor capable of repeatedly decreasing the
production of IL-10 in hMDSCs. Like Chapter 2, an in silico analysis was used to
predict the physiological parameters and absorption, distribution, metabolism, and
elimination (ADME) characteristics of test compounds. Based on these findings, both
FH535 and ICRT14 demonstrate attributes that encourage further evaluation in the
context of improving immunotherapy outcomes in solid tumors.
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CHAPTER 1

INTRODUCTION

1.1 Types of cancer and their current implications
In the United States alone, it is predicted that nearly 1.9 million individuals were
diagnosed with some form of cancer in 2021. Of that group, it is estimated that more
than 600,000 people will die of their disease (Cancer of Any Site - Cancer Stat Facts,
n.d.). Globally, an estimated 19.3 million new cancer cases and more than 9 million
cancer deaths occurred in 2020. Breast cancer (female) was the most common cancer
diagnosis, with an estimated 2.3 million new cases and representing 11.7% of all
cancer diagnoses. Lung cancer incidence was not far behind at 11.4%, followed by
colorectal, prostate, and stomach cancers at 10.0%, 7.3%, and 5.6%, respectively.
Cancer of the lung remained the deadliest form of cancer, with an estimated 1.8
million deaths representing 18% of all cancer-associated mortalities. The next
deadliest malignancies were colorectal and liver cancers, respectively responsible for
9.4% and 8.3% of cancer deaths worldwide. Cancer related illnesses are expected to
grow to 28.4 million cases in 2040; this figure may be further exacerbated due to
increasing risk factors associated with ever-growing economies and modern lifestyles
(Sung et al., 2021).
While the above estimates may vary based on regional lifestyles and access to
modern medicines, it is still astonishing to consider the frequency and lethality of this
complex disease. Improving global education on the prevention and treatment options
in developing and transitioning countries will be vital for managing future incidence
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rates. Encouragingly, the tools for treating cancer have expanded considerably over
recent years with increasing successes from surgery to chemotherapy and within the
past decade, immunotherapy (Sung et al., 2021).
Though there are many ways to classify cancer, designating them as either solid
or liquid tumors is particularly useful in the context of immunotherapy. Solid tumors
are regarded as a solid mass, or many masses, capable of growing in organ systems
and can occur anywhere in the body (e.g., lung cancer). Liquid tumors, on the other
hand, are in constant circulation originating from the blood, bone marrow, or lymph
nodes (e.g., types of leukemia, lymphoma, myeloma) (Ma et al., 2019; Z.-Z. Zhang et
al., 2022). Both forms of cancer are similar in that they are defined by the
development of abnormal cells that multiply uncontrollably.
1.2 Current leading immunotherapeutic strategies
Immunotherapy can be defined as the boosting of a host’s natural defenses for the
elimination of malignancies. To date, immunotherapeutics have been implemented in
various forms including oncolytic virus therapy, cancer vaccines, cytokine therapy,
adoptive T-cell therapy (ACT), and immune checkpoint inhibitors (ICIs) (Y. Zhang &
Zhang, 2020). In recent years, both ACT and ICIs have demonstrated particular
clinical efficacy in the treatment of malignancies, indicating their utility in
immunomodulation for executing or facilitating tumor-elimination (Ahmad et al.,
2020; Han et al., 2021; Ma et al., 2019; Martino et al., 2021; Melenhorst et al., 2022).
And though the other mentioned immunotherapies have demonstrated modest
efficacy, the contents of this thesis are more applicable to the enhancement of AC and
ICI therapies (Conlon et al., 2019; Donninger et al., 2021; Pearl et al., 2019).
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One form of ACT utilizes tumor-infiltrating lymphocytes (TIL), taking advantage
of immune cells that are already capable of targeting and penetrating the tumor site.
Specifically, TILs are harvested from a patient’s tumor, cytokine-induced for
activation and expansion, and then re-infused into the patient. While the use of TILs in
the treatment of solid tumors (e.g., melanoma) has demonstrated distinguished
efficacy in early clinical studies, no treatments have been approved by the U.S. Food
and Drug Administration (FDA) (Jiménez-Reinoso et al., 2021). Engineered T-cell
receptor (TCR) therapy involves the addition of tumor-antigen specific TCRs to naive
T cells; doing so enables a T cell to specifically target class I and II major
histocompatibility complexes (MHCs) on the surface of cancer cells with the help of
costimulatory molecules (e.g., CD28) (Tsimberidou et al., 2021). Chimeric antigen
receptor-modified T (CAR T)-cell therapy is one form of ACT that has demonstrated
efficacy in the treatment of hematological malignancies and has recently been praised
for its curing of two patients with chronic lymphocytic leukemia (Han et al., 2021;
Melenhorst et al., 2022; Z.-Z. Zhang et al., 2022). CAR T cells are genetically
engineered to express a single-chain variable fragment (scFv) capable of identifying
and targeting specific cancer cells in an MHC-independent manner. Upon recognition
of a cancer-associated surface antigen, the scFv facilitates binding of a CAR T cell to
the cancer cell; within the CAR T cell, an intracellular cascade is triggered to
ultimately cause the cancer cell to be eliminated (J. H. Park et al., 2016; J. H. Park &
Brentjens, 2010). Similarly, CAR-NKs make use of innately cytotoxic natural killer
(NK) cells by bioengineering a CAR on their surface to specifically target
malignancies (Xie et al., 2020). Thus, the primary difference between TCRs and
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CARs is the ability of the latter to recognize antigens not presented by MHCs.
Interestingly, TCRs may be more effective in the treatment of solid tumors due to their
encountering of intracellular antigens presented by MHCs; antigens from within tumor
cells are often more unique than those on the surface of cancer cells, lending the
advantage of specificity to TCRs (Tsimberidou et al., 2021) .
ICIs, on the other hand, cleverly exploit the mechanisms described above to
reactivate T cell response and improve tumor elimination. When TCRs are presented
tumor-associated antigens by the major histocompatibility complex (MHC) on tumor
cells or antigen presenting cells (APCs), the immune response of the T cell depends on
co-stimulatory factors (e.g., CD28) to amplify the signal. However, even in the
presence of foreign antigens, adherence of co-inhibitory checkpoint molecules,
programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T
lymphocyte antigen-4 (CTLA-4) can suppress T cell function, thus facilitating tumor
evasion and growth. As PD-1 binds PD-L1 on a tumor cell or CTLA-4 binds
CD80/CD86 on an APC, immune activity of the stimulated T cell is suppressed (Yan
et al., 2020). Though this checkpoint complex prevents autoimmunity, it also shields
tumor cells from immune cell recognition and facilitates unchecked tumor growth
(Alsaab et al., 2017). Therefore, immune checkpoints have become major targets of
interest in biologic and small molecule drug development (W. M. Smith et al., 2019;
Q. Wu et al., 2021).
Success rates of the therapies described here are largely dependent on the type
and location of the cancer. This disparity is largely due to the immunosuppressive
environment associated with solid tumors. Essentially, these forms of cancer can alter
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the phenotypes of surrounding cells to reduce immune response and effectively evade
clinically boosted natural tumor immunity (Osipov et al., 2019; Y. Zhang & Zhang,
2020; Z.-Z. Zhang et al., 2022). Thus, understanding the mechanisms and phenotypic
traits of key cellular players in this environment is imperative for the improvement of
immunotherapeutic outcomes.
1.3 The tumor microenvironment (TME)
Perhaps the most challenging avenue to address in solid tumor chemotherapy and
immunotherapy alike is the dynamic and organ-specific conditions for cytokine
production and cellular defense mechanisms that mitigate drug penetration and
immunotherapy efficacy (Osipov et al., 2019; Y. Zhang & Zhang, 2020). The everchanging physical barrier constructed by stromal cells, immunosuppressive myeloidderived suppressor cells (MDSCs) in tandem with regulatory T cells (Tregs), leads to
effective immune evasion from cytotoxic T lymphocytes (CTLs) and deactivates
CAR-T therapies (Siret et al., 2020; Tomić et al., 2019; D. Wang et al., 2018). The
efficacy of immunotherapies, like ICI and ACT, is dependent upon specific
characteristics of a patient’s TME. For example, an “immune inflamed” tumor with
relatively high tumor-infiltrating lymphocyte (TIL) counts, low MDSC, and baseline
Treg counts is the perfect candidate for these immunotherapies (Cogdill et al., 2017;
Whiteside, 2008). Conversely, a TME consisting of high MDSC and Treg counts can
continue to suppress CTLs, resulting in resistance to immunotherapy (D. S. Chen &
Mellman, 2017; F.-F. Chen et al., 2020; Darvin et al., 2018; Gattinoni et al., 2006).
Though several cell types are responsible for the TME’s immunosuppressive
characteristics, MDSCs are the communicative “quarterbacks” that stimulate Tregs,
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recruit TAMs, suppress the anti-tumor activity of NK cells and CTLs, and promote
tumor immune evasion by inducing increased expression of immune-inhibitory surface
proteins like PD-L1 (S.-M. Park & Youn, 2019). TAMs present yet another hurdle for
immunotherapies to address as polarized TAMs and MDSCs not only secrete protumorigenic cytokines but further recruit other macrophages and MDSCs to maintain
tumor homeostasis and metastasis in distant tissues (Kumar et al., 2016). MDSCs are
considered the nexus in this TME puzzle and have become the subject of numerous
drug development programs. MDSC biology has advanced the field in how tumors are
treated and therefore represent a significant source of new chemical development
efforts. MDSC glutamine metabolism, depletion of arginine by arginase-1, conversion
(i.e., depletion) of tryptophan, and production of kynurenine by indoleamine 2,3
dioxygenase 1 (IDO1) have been viewed as potential targets for MDSC modulation,
with promising preclinical but limited substantiating clinical evidence (H. Li et al.,
2019; L. Li et al., 2018; Öztürk et al., 2021; Y. Wang et al., 2020). Moreover, MDSC
plasticity in various metastatic tumor sites present tissue specific proteomic targets
that may be tractable and provide clinical utility in tandem with immunotherapies
(Guha et al., 2019). CD33+ MDSCs, which mostly consist of M-MDSCs, represent a
vastly immunosuppressive MDSC phenotype, which correlates to poor patient
prognosis in multiple cancers (Cassetta et al., 2019; Kumar et al., 2016). In Chapter 2
of this thesis, the specific biomarkers and physiological functions of different MDSCs
are defined in greater detail.
Considering their influence on immune cells, MDSCs represent a potential cotarget for dual administration (small molecule + immunotherapy) to modulate the
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immunosuppressive TME and increase the efficacy of immunotherapies (Anani &
Shurin, 2017; Bronte et al., 2016). To substantiate this theory, clinical studies
investigating the ability of both synthetic and natural product-based small molecules
(e.g., gemcitabine, all-trans-retinoic acid, entinostat, metformin) to modulate MDSCs
and increase the therapeutic potential of ICI therapy are already underway (Lim et al.,
2020). Likewise, there also exists a growing interest in the capability of small
molecules to prime the TME for other immunotherapies, namely ACTs (Lim et al.,
2020; S. Park et al., 2021; Rosen et al., 2016). Small molecules capable of modulating
the TME for this purpose can be referred to as chemo-immunotherapeutic agents
(CIAs).
1.4.1 Biologics vs CIAs as adjuvants for improving immunotherapeutic outcomes
The efficacy of biological adjuvants in combinatorial immunotherapy is currently
being explored. As mentioned earlier, ICIs can inhibit immunosuppressive
mechanisms in the TME and bear clinical utility with proven efficacy in the treatment
of non-small cell lung cancer, renal and hepatocellular carcinoma, melanoma,
bladder/head/neck cancer, Merkel cell carcinoma, MSI-high colorectal carcinoma, and
breast cancer (Ribas & Wolchok, 2018). Recent studies have implemented dual
biological (mAb) ICI and CAR T-cell therapy for the treatment of solid tumors,
demonstrating a 72% response rate and complete metabolic responses in two of eleven
patients (Grosser et al., 2019). Additionally, combined CAR T-cell and oncolytic virus
therapy was found to enhance T-cell infiltration, reduce metastases, and prolong
survival in mice compared to monotherapy (Watanabe et al., n.d.; Wing et al., 2018).
Unfortunately, treatments that involve biological agents like mAbs and oncolytic
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viruses are notoriously expensive. They may induce severe adverse effects due to
immunogenicity and possess suboptimal tumor-permeability properties relative to
CIAs (Liu et al., 2021).
CIAs that target the binding sites, reduce expression, or induce degradation of
immune checkpoint molecules are mostly in the preclinical drug development stage
(F.-F. Chen et al., 2020; Osipov et al., 2019; Q. Wu et al., 2021; Zhan et al., 2016).
Due to the growing number of MDSC-targeting agents available on the market, some
of which are already FDA-approved for use in patients, CIA-induced MDSC
modulation is being explored as an adjuvant mechanism for improving patient
prognoses. CIAs capable of reducing the immunosuppressive functions of MDSCs are
inhibitors of cyclooxygenases-2 (COX-2), indoleamine 2,3-dioxygenase 1 (IDO1), and
nitric-oxide synthase (NOS), among others (Lim et al., 2020). Encouragingly,
researchers are now shifting their focus to the identification of unexplored
mechanisms for immunomodulation of MDSCs (K. Li et al., 2021). Specific targets
theorized to be involved in MDSC-mediated immunosuppression include, but are not
limited to, STAT3, phosphodiesterase type 5 (PDE5), γ-secretase, and AMP-activated
protein kinase (AMPK) (Lim et al., 2020). Therefore, the design and evaluation of
potential CIAs for improving other forms of immunotherapy is of growing interest,
representing an opportunity for molecular discovery and optimization. As previously
mentioned, the distinct phenotypic properties associated with MDSCs may harbor
potential co-targets for dual administration of CIAs and adoptive T cells.
1.4.2 “Omics” approaches for identifying pharmacologic targets in the TME
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In the context of solid tumors, it is desirable to modulate the behavior of MDSCs
in the TME for improving immunotherapeutic efficacy, and though the previously
discussed methods of MDSC modulation are promising, the exploration of alternative
mechanisms and their downstream effects are also valuable. Thus, it is useful to
identify many potential targets specific to MDSCs and/or other cells implicated in an
immunosuppressive TME. Augmenting this search, recent technological advances
have enabled the global visualization of cellular processes. Essentially, “omics”
approaches can capture biological snapshots to elucidate changes across experimental
samples at different physiological perspectives (e.g., genome, epigenome,
transcriptome, proteome, lipidome, metabolome, etc.) (Hasin et al., 2017).
Genomics and epigenomics can be defined as the global analyses of genes and
chromosomal modifications, respectively. Because the genome of an organism
remains relatively constant, it is currently being used as a reference for population
studies (e.g., gut microbiome) (Kinross et al., 2011; Tilg & Kaser, 2011). The
epigenome can also be studied to determine changes in genetic expression caused by
reversible chemical modifications to the DNA and its chromosomal structure.
Transcriptomics, concerning RNA, can be used to identify and quantify individual
genes being expressed in a sample. Similarly, proteomics approaches can be used to
measure RNA translation by the presence of proteins in much the same way (Micheel
et al., 2012). Techniques for these measurements have also evolved over time,
enabling rapid recording and comparison of sample transcriptomes by RNAsequencing or global proteomic snapshots using tandem mass spectrometry (MS/MS)analyses (Gilchrist et al., 2020). Likewise, the small molecules comprising the
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metabolome of a sample can be accurately assessed by NMR and, more recently, MSbased methods (Reo, 2002; Zhou et al., 2012).
Yielding large datasets, these global analysis methods are convenient for pattern
recognition and populational phenotypic analysis. Various statistical techniques can be
employed to process these results, revealing a myriad of characteristics including
differential gene expression (e.g., Log2FC), phenotypic similarities, and the presence
or absence of small molecule metabolites in association with varying experimental
conditions (Micheel et al., 2012). Open-source platforms like the drug–gene
interaction database (DGIdb) and PHAROs drug–target development data mining
software have demonstrated utility in the filtering of proteomics data to reveal
druggable targets warranting further validation and translational studies (DaSilva et
al., 2021; Freshour et al., 2021; Sheils et al., 2021). Data indicating potential
biomarkers or drug targets can be validated using computational protein analyses or
other preclinical experiments (Chang et al., 2010).
Considering the complexity of the TME, global MS-based proteomics may be
useful in the illumination of new drug targets specific to MDSCs (H. Li et al., 2019).
Recent studies have employed sequential analysis of all theoretical mass spectra
(SWATH)-MS technology to measure the expression of proteomic targets on murine
MDSCs from murine lung and liver metastases. In this study, proteomic data was
collected using a SWATH-MS method, compared to previously acquired RNAsequencing data, analyzed for organ-specific protein expression, and filtered for
druggability in a multi-omics approach for identifying unique targets on murine
MDSCs (DaSilva et al., 2021; Guha et al., 2021; Hasin et al., 2017). The results from
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these SWATH-MS analyses are used in the following chapters as a reference for
selecting potential new drug targets in MDSCs. as well as a method of measuring
phenotypic responses of donor peripheral blood mononuclear cells (PBMCs) to
experimental conditions. Following the identification of potential targets on MDSCs,
the abilities of various CIAs to exert immunomodulatory influence can be evaluated
through a variety of methods.
1.5 Experimental validation and development of targets
The drug development process typically begins with a theorized target or
mechanism that is later validated by an assortment of in silico, in vitro, ex vivo, and in
vivo experiments. By using a variety of in silico methods, scientists can model
potential target-ligand interactions, predict the probability of off-target activity,
analyze the absorption/distribution/metabolism/elimination (ADME) characteristics,
or visualize the potential downstream influences of any proposed molecular structure
(Daina et al., 2017, 2019; Forli et al., 2016). These computational techniques, as well
as many others, are cheap and accessible for supporting research hypotheses and
facilitating the design of future experiments (F. Wu et al., 2020).
In silico methods can be used to identify and assemble a library of analogous
small molecules for in vitro testing (Bragina et al., 2022). Usually, the first in vitro
experiment involves measuring the test compounds’ cytotoxicities on a cell type
relevant for supporting the hypothesis. Examples of methods for measuring compound
cytotoxicity include [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
(MTT), lactate dehydrogenase (LDH), and CellTiter-Glo (CTG) assays which measure
mitochondrial activity, membrane damage, and cellular ATP, respectively (Flobak et
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al., 2019; Vinken & Blaauboer, 2017). Results from these experiments can be used to
determine proper drug concentrations for future assays. The following experiments are
selected based on the study’s aims to observe whether an intended bioactivity is taking
place. For example, immunosorbent assays measuring the presence of
immunosuppressive cytokines, such as IL-10, in cell media could be used to determine
a CIA’s immunomodulatory influence on MDSCs (Bronte et al., 2016; Mittal et al.,
2015; L. K. Smith et al., 2018). As a logical next step, multiplexed cytokine analysis
might then enable a more detailed elucidation of MDSC-response to test compounds
(Veglia et al., 2021).
While the results of an in vitro study may provide initial evidence of a desired
bioactivity, further studies are necessary to confirm these findings. Preclinical in vivo
experiments are generally conducted in animals, typically mice, that are subjected to
various experimental conditions and treated with the proposed drug for identification
of its pharmacokinetic and pharmacodynamic properties. Results from these
experiments are intended to translate into experimental design for the clinical
treatment of human disease (Andrade et al., 2016; Tuntland et al., 2014). Interestingly,
several studies have demonstrated the ex vivo culturing of donor immune cells in the
presence of immortal tumor spheroids (Augustine et al., 2015; Nyga et al., 2016;
Shelton et al., 2021; Thakur et al., 2013). Likewise, organ-on-a-chip and microfluidic
technology provide alternative platforms for studying drug response in physiologically
relevant environments (Adriani et al., 2016; Pavesi et al., 2016).
1.6 Concluding remarks and future directions of tumor immunology
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The ability of immune cells to naturally eliminate solid tumors are highly
dependent on cell-cell chemical signals exchanged within the TME. This challenge
translates to challenges in the treatment of solid tumors, shifting the focus of research
to the exploration of immunomodulatory targets on tumor-associated immune cells.
Human MDSCs (hMDSCs) are of particular interest in this research, being generated
from healthy donor blood for use in target-validation experiments. CD38 and βcatenin are two such targets reported in the MDSCs of murine liver and lung
metastases, respectively (DaSilva et al., 2021). Thus, Chapters 2 and 3 of this thesis
describe investigations into the validity of these targets by evaluating interacting CIAs
for their ability to modulate the immunosuppressive phenotypes of hMDSCs.
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Abstract
Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T
(CAR T)-cell therapy, are promising approaches for treating hematological
malignancies. However, the tumor microenvironment (TME) around solid tumors
(e.g., lung and liver cancer) presents challenges different from those of blood-based
malignancies (e.g., leukemia, lymphoma, etc.). Myeloid-derived suppressor cells
(MDSCs) in the TME secrete immunosuppressive cytokines that diminish the efficacy
of immune cells for tumor-elimination. Recent studies show that the glycoprotein,
CD38, is associated with the immunosuppressive MDSC populations within the TMEs
of murine liver metastases with several flavonoid and synthetic molecules capable of
competitively inhibiting its enzymatic activity. In this study, we determined the
cytotoxic ranges of synthetic and flavonoid CD38 inhibitors against MDSCs
differentiated from the PBMCs of healthy human donors (hMDSCs) and their
autologous T cells. Due to favorable toxicity profiles, the test compounds were
evaluated for their influence on key immunomodulatory cytokines in hMDSCs.
Treatment of hMDSCs with 78c caused decreased production of immunosuppressive
IL-10, CCL17, and MMP7 by as much as 66%, 60%, and 40%, respectively. At the
same time release of CCL4 and IL-1β was increased by 191% and 148%, respectively.
Finally, in silico analyses predicting protein-ligand interactions, pharmacokinetic
characteristics, and in vivo specificity of anti-CD38 compounds were performed.
Results from these experiments indicated that 78c possesses favorable inhibitory
action and pharmacokinetic attributes, warranting further evaluation of its
immunomodulatory potential in vivo.
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Introduction
CAR T-cell therapy has demonstrated impressive efficacy in treating hematological
malignancies.1,2 Last year, the first CAR T-cell therapy for treating multiple myeloma
(MM) was approved by the FDA, marking the fifth approved therapy of its kind.1 A
recent study revealed that CAR T-cell therapy was able to cure leukemia in two
patients, as demonstrated by decade-long remissions and the persistence of CD4+ CAR
T cells. This success encourages a shift in focus among the research community for
placing a future emphasis on improving the efficacy of immunotherapy in solid
tumors. A daunting obstacle for the expanded use of immune cell therapies for solid
tumors are the localized TMEs that harbor tumor-protective immune suppressor cells.2
There are several types of immune suppressor cells that are induced by cytokines in
the TME, including MDSCs, regulatory T cells (Tregs), and tumor-associated
macrophages (TAMs).2,3 The inducing cytokines include granulocyte‐macrophage
colony‐stimulating factor (GM‐CSF), granulocyte colony‐stimulating factor (G‐CSF),
prostaglandin-E2 (PGE2), interleukin (IL)-6, CCL2/3, and CXCL1/2, among others.3,4
MDSCs are immature myeloid cells that primarily target T lymphocytes through
secretion of arginase 1 (Arg1), nitric oxide (NO), IL‐10, transforming growth factor
(TGF)‐β, and cyclooxygenase (COX)-2.3 Though there are several mechanisms by
which MDSCs suppress T-cell activity, IL-10 is known to directly suppress CD8+ T
cells and the ability of dendritic cells (DCs) and macrophages to stimulate the
proliferation of antigen-specific CD4+ T cells.5,6 Further, MDSCs can induce the
upregulation of Tregs and TAMs.3,7 Thus, MDSCs appear to play a pivotal role in
reducing immunotherapeutic efficacy.

32

MDSCs can be classified into two categories: monocytic (M)-MDSCs and
polymorphonuclear (PMN)-MDSCs with CD11b+/CD14+/CD15-/CD33+ and
CD11b+/CD14-/CD15+/CD66b+ phenotypes, respectively.8 Though these
classifications share some characteristics, an accepted surface protein for MDSCspecific cell sorting is CD33.8,9 CD33+ selection results in a mixed group of MDSCs
that includes more “immature” progenitors referred to as early-stage (e)MDSCs.8
Beyond the aforementioned surface proteins, proteomic evaluation of MDSCs
suggests the possibility of targeting specific immunosuppressive pathways in an
organ-specific manner. One such druggable target that may act in MDSC-mediated
immunosuppression is CD38, which has been found to appear predominantly on
MDSCs from murine liver metastases.10–12
CD38 is a transmembrane glycoprotein found most prominently on the surface of
hematopoietic stem cells; B, NK, and T lymphocytes; and plasma cells.13 Because
MDSCs are derived from the immature myeloid cells (IMCs) in the bone marrow,
CD38 becomes involved in their phenotype through stimulation by various cytokines,
endotoxins, and interferon.14,15 Less clear, however, is the dynamic role this
glycoprotein plays across its expression on various cell types. As an enzyme, CD38 is
a cyclic ADP ribose (cADPR) hydrolase; hence, it is a consumer of NAD+ in the
production of cADPR, ADPR, and nicotinic acid adenine dinucleotide phosphate
(NAADP).13 As a myeloid cell receptor, CD38 is associated with the protein c-Cbl in
helping direct the differentiation process of these cells through a mitogen-activated
protein kinase (MAPK) pathway.16 A murine-based study of esophageal cancer found
that CD38high MDSCs possessed greater immunosuppressive and tumor-promoting
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capacity than CD38low MDSCs using a T-cell suppression assay and in vivo tumor
volume assessment. This association was later validated by phenotypic differences in
CD38high/low populations including increased production of inducible nitric oxide
synthase (iNOS) from CD38high MDSCs, a marked promotor of tumor growth and
survival.17 Another study of advanced colorectal patients found a significant
upregulation of CD38+ M-MDSCs compared to healthy volunteers.18
The FDA-approved CD38-targeting antibody, daratumumab, has recently been of
interest in the treatment of multiple myeloma.1,19 One study noted the drug had
significant effects on CD3+/CD4+/CD8+ T-cell proliferation, demonstrating an average
increase of about 44%, 32%, and 62%, respectively, per 100 days.20 Further, various
anti-CD38 antibody therapies reportedly increased immunoreactivity of Th17 and
CD8+ T cells in chronic lymphocytic leukemia models.21 Though CD38 inhibition
alone is speculated to increase control within the TME, CD38 inhibition may
potentially increase the efficacy of anti-tumor adoptive T-cell therapy, with organspecific potential in the liver10,22 (Fig. 1).
Although there are currently no reports of small molecule CD38 inhibitors being used
to modulate the TME for the purpose of MDSC immunomodulation, compounds that
target CD38 have been identified. For example, studies of natural products have
shown that the flavonoids luteolinidin, kuromanin, and cyanidin are inhibitors of
CD38 (IC50 = 6.0 μM, 6.3 μM, and 21.8 μM, respectively).23,24 Thus, analogs of
kuromanin are theorized to inhibit CD38 in a similar manner. Crystallographic data of
CD38 has also allowed for the design of more specific and potent CD38 inhibitors.
One potent compound, 78c (IC50 = 7.3 nM), binds primarily via hydrophobic
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interactions with Trp176, a non-catalytic residue in the active site important for CD38
inhibition. Though this mode of inhibition is considered competitive, it does not
require an interaction at the protein’s catalytic residue, Glu226.25
In this study, human MDSCs (hMDSC) from healthy donors were used to investigate
the cytotoxic and immunomodulatory effects of various CD38 inhibitors (Fig. 2).
Implications of experimental observations are discussed, considering the potential
causes and downstream impacts of CD38 inhibition on the TME. The ability of known
CD38 inhibitors to bind to their respective protein targets and their projected
pharmacokinetic properties are also evaluated using in silico approaches. To this end,
existing in vivo data are discussed and interpolated with results from this study to
generate a drug development framework for improving the outcomes of adoptive Tcell therapies.
Materials and methods
Differentiation of donor PBMCs to CD33+ hMDSCs
Healthy human donor apheresis chambers (LRS) were obtained from the Rhode Island
Blood Center (Providence, RI). Qualified donors were required to be between the ages
of 18-50 yr with no preexisting health conditions or use of immunosuppressive drugs.
PBMCs were isolated using ficoll-paque (Cytiva, Marlborough MA) density gradient
centrifugation according to Cytiva’s procedures. Briefly, contents were transferred
onto 15 mL Ficoll-Paque Plus in 50 mL tubes for centrifugation in an Eppendorf
5804R (Eppendorf, Hamburg, Germany) at 1700 rpm for 30 minutes with low
acceleration and no brake. To obtain PBMCs, Ficoll-separated monocytes were
aspirated using 10 mL serological pipettes and washed in a separate 50 mL tube by
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centrifuging at 1700 rpm for 7 minutes. PBMCs were then enumerated using trypan
blue dye exclusion on a Nexcelom Cellometer before separating for T cells using
dextran coated magnetic bead separation (StemCell Technologies, Vancouver,
Canada). T cells were then cultured in T75 flasks at a density of 5x106 cells/mL with
ImmunoCult™-XF T Cell Expansion Medium (StemCell Technologies).
Negative cells were placed into T75 flasks at a density of 5x106 cells/mL and cultured
as described by Tomić et al. to generate human MDSCs.4 Specifically, RPMI1640
Media (Life Technologies, Waltham, MA) was supplemented with 10% Fetal Bovine
Serum (FBS) (Life Technologies), 1% Penicillin/Streptomycin (Life Technologies),
and a combination of IL-6 (Biolegend, San Diego, CA), GM-CSF (Biolegend), and
Prostaglandin E2 (PGE2, R&D Systems, Minneapolis, MN) for 3-7 days; cells
collected on Day 3 and Day 7 were used for LC-MS/MS proteomic analyses (see
below), while cells collected on Day 5 were primarily used for cell-based assays.
hMDSCs were isolated from the harvested cells using a CD33+ immunomagnetic
positive selection kit (StemCell Technologies) according to the manufacturer’s
protocol.
Cell viability assay for evaluation of compound cytotoxicity on hMDSCs and T
cells.
CD38 inhibitors kuromanin, cyanidin, hesperidin, myricitrin, rutin, and 78c (all from
MedChemExpress LLC, Monmouth Junction, NJ) were evaluated for cytotoxicity
against hMDSCs and T cells. The respective cell types were added to wells at 5x105
cells/mL in white-walled 96-well plates and treated with compounds at concentrations
ranging between 100, 10, 1, 0.1, 0.01, and 0.001 µM, or were treated with 0.1%
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DMSO (vehicle control). After 24 h, CellTiter-Glo 2.0 Cell Viability Assay kits
(Promega, Madison, WI) were used according to manufacturer protocol to measure the
presence of ATP in response to compound treatment. Briefly, 100 µL CellTiter-Glo
2.0 reagent was added to wells with 100 µL cell media; luminescence was recorded on
a SpectraMax ID3 Plate Reader (Molecular Devices, San Jose, CA) and cell viability
was analyzed on GraphPad with DMSO controls representing 100% cell viability.
MDSC stimulation and cytokine analysis
CD33+ MDSCs were seeded in 48-well plates at a density of 1x106 cells/mL.
Lipopolysaccharide (LPS, Sigma Aldrich) and interferon-gamma (IFN-γ, Biolegend)
were added concomitantly with vehicle (DMSO, 0.1% v/v), with or without compound
(5, 1, and 0.1 µM), and incubated for 24 h. Cell culture media was then collected and
stored at -80°C for cytokine analysis. Media was initially analyzed for IL-10 content
by ELISA according to manufacturer (Biolegend) instructions and using manufacturer
supplied reagents. Media was also profiled for the production of other cytokines using
three different panels for multiplexed analysis (IL-10, IL-12(p70), IL-13, IL-17A, IL15, CCL2, CCL4, CCL17, TNFα, IL-1β; IL-10, TNFα, IL-1β, IL-8; MMP7, MMP9,
MPO) on an Ella cytokine multiplexing instrument (Protein Simple, San Jose, CA)
according to the manufacturer’s protocol for Simple Plex Assays.
Data Analysis
Cytotoxicity, ELISA, and multiplex data were analyzed using Graphpad Prism (Ver 9,
La Jolla, CA) statistical software. Comparisons between ELISA and multiplex
samples were performed by paired t-tests or one-way analysis of variance (ANOVA)
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where appropriate, and statistical significance was determined as * P ≤ 0.05 ** P ≤
0.01 *** P ≤ 0.001 **** P ≤ 0.0001.
Molecular docking analysis of crystallographic CD38 and respective ligands
The PDB ID: 1YH3 CD38 structure was selected for molecular docking studies
because it contains no additional molecules or genetic mutations and has a favorable
x-ray diffraction resolution of 1.91 Å. The 1YH3 file contains two CD38 molecules (A
and B chain) in the crystallographic asymmetric unit. Considering that each domain
houses 252 residues, they are presumed to be biologically equivalent, thus allowing
for splitting of the domains prior to in silico analysis using UCSF Chimera 1.15.26 The
A chain was then prepped for docking experiments using the Dock Prep feature of
Chimera to delete water molecules/solvent and non-complexed ions, repair
truncated/incomplete side chains using the Dunbrack 2010 Rotamer library, and add
hydrogens.27 Following this, the molecule and test compounds were imported into the
PyRx program, minimizing the energy of the latter to prepare for ligand docking.28 For
this study, docking interactions of NAD+ and NMN+ were compared to those of
kuromanin, cyanidin, and 78c. Using the (AutoDock) Vina Wizard in PyRx, ligand
docking was performed with Exhaustiveness: 50 and grid coordinates enclosing the
binding site of CD38 inhibitors as determined in preliminary docking studies with
Exhaustiveness: 8. Vina’s output included nine distinguished conformational models
with differing root-mean-square deviation (RMSD) values, indicating atomic flexion
respective to the first model. Using metformin as a negative control and endogenous
CD38 ligands, NAD+ and NMN+, average binding affinities for the top 9
conformations were used to confirm the validity of docking outputs (Supplementary
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Fig. S2; endogenous ligand structures shown in Supplementary Fig. S1); the most
common interactions observed across all of a compound’s conformations are noted
and cross-referenced with literature to support model validity.24,25,29–31 The top
conformer of docked CD38 and its respective ligands were exported in .pdb format for
2D and 3D ligand interaction analysis in BIOVIA Discovery Studio 2021.32 All
residues shown in figures are 44 amino acids below those in CD38’s UNIPROT
sequence (e.g., Glu226 is shown as Glu182 in figures).
In silico drug-likeness analysis and target prediction of CD38 inhibitors
The SMILES data for known CD38 inhibitors were entered into open-source
programs, SwissADME (http://www.swissadme.ch/) and SwissTargetPrediction
(http://www.swisstargetprediction.ch/). SwissADME was used to predict key
physiological parameters such as water solubility, lipophilicity, pharmacokinetics, and
likelihood to permeate cell membranes (Table S1). SwissTargetPrediction was used
with Homo sapiens as the target organism to estimate the probability (%) of a
compound targeting CD38 in the body (Table S2).
Results
Differentiation of donor PBMCs to CD33+ hMDSCs
All donor PBMCs were processed in accordance with their intended applications
following differentiation. These applications included CellTiter-Glo viability assays,
various immunosorbent assays, and total protein analyses using Sequential Window
Acquisition of All Theoretical Mass Spectra (SWATH-MS) (data not shown). Because
each donor was used for investigating different endpoints, their appearance in the
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following sections is not chronological; for reference, their respective differentiation
methods and subsequent experimental applications can be found in Table 1.
Evaluation of cytotoxicity on hMDSCs and T cells by CD38 inhibitors
Various CD38 inhibitors were then tested for cytotoxicity against autologous T cells
and hMDSCs. First, the viability of T cells from Donor 1 was evaluated after 24 h
following the addition of the CD38 inhibitors, kuromanin and 78c. Both compounds
demonstrated cytotoxicity (< 70% cell viability) to T cells at 100 μM. Cytotoxicity
was greatly reduced at 10 μM with no significant toxicity observed at lower
concentrations (Supplementary Fig. S3). Donor 2 was used to test these compounds’
cytotoxic effect and calculate their IC50 values on both T cells and hMDSCs. Results
from this experiment confirm previous results, revealing IC50 values >20 μM for 78c
and kuromanin in both cell types (Fig. 3a, b). Kuromanin analogs cyanidin, hesperidin,
myricitrin, and rutin, were evaluated for cytotoxicity on T cells and hMDSCs from
Donor 10. Each demonstrated IC50 values >100 μM for both cell types, except for
cyanidin (T cells: 5.72 μM; hMDSCs: 27.4 μM) and myricitrin (T cells: 3.80 μM;
hMDSCs: 22.1 μM) (Fig. 3c-f). Results from these experiments indicate that a dose
range between 10 and 1 μM will allow the compounds to modulate the hMDSCs
without significant reductions in cell viability, thus compound concentrations of 5, 1,
and 0.1 µM were selected for subsequent cytokine analyses. Notably, all compounds
were capable of inducing T-cell proliferation at one or more of the tested
concentrations, resulting in viabilities greater than 100% (Fig. 3a-f).
Stimulation with IFN-γ and LPS needed to induce immunosuppressive hMDSC
phenotype
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IL-10 production by Donor 5 hMDSCs was measured by ELISA in response to
ICRT14 treatment, with or without the initial cell exposure to 50 ng/mL IFN-γ for 6 or
24 h. Results from all doses and timepoints in this experiment indicated that the
CD33+ (pre-)hMDSC model required further inflammatory stimulation to increase IL10 production (Supplementary Fig. S4a). Stimulation of hMDSCs from Donor 6 with
500 ng/mL LPS and 100 ng/mL IFN-γ directly before treatment with the test
compounds led to a saturation in the IL-10 (Supplementary Fig. S4b). Therefore,
inflammatory stimulation of hMDSCs was decreased to 150 ng/mL LPS and 75 ng/mL
IFN-γ.
Modulation of hMDSC cytokine release by CD38 inhibitors
Treatment of stimulated hMDSCs from Donor 7 with 78c induced 45% and 60%
reductions in IL-10 and CCL17, respectively, in cells treated with 78c at 5 μM (Fig.
4a, d). At the same time, production of IL-1β and CCL4 were increased, respectively,
by 148% and 191% upon treatment with 78c at 5 μM. (Fig. 4b, c). A 141% increase in
CCL4 was also observed in hMDSCs treated with 78c at 1 μM. A separate analyte
panel on hMDSCs from Donor 8 revealed 66% and 26% reductions of IL-10 at drug
concentrations of 5 and 1 μM, respectively (Fig. 4e). MMP7 signal was also reduced
by 40% in response to treatment with 78c at 1 μM (Fig. 4f). No significant
modulations of other measured cytokines (IL-12(p70), IL-13, IL-17A, IL-15, CCL2,
TNFα, IL-1β, IL-8, MMP9, MPO) were observed (Supplementary Figs. S5, S6) In
comparison, the flavonoid inhibitors kuromanin, cyanidin, hesperidin, myricitrin, and
rutin demonstrated relatively marginal IL-10 reduction in hMDSCs from Donor 9
treated at concentrations ranging from 1-5 µM (Supplementary Fig. S7a). These
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effects were not observed when repeated with cells from Donor 10 (Supplementary
Fig. S7b)
In silico analysis of docking interactions and drug-likeness characteristics of
CD38 ligands
Using computational molecular modeling, the CD38 ligands were evaluated for their
respective binding potentials. The first tested compound was a negative control,
metformin. When forced to dock in the same location as the other tested compounds,
metformin exhibited an average affinity of -4.5 kcal/mol. Thus, the negative control
bound CD38 with lower energy in comparison to CD38’s endogenous ligand, NAD+.
The top NAD+ conformation included a conventional hydrogen bond at the catalytic
domain, Glu226 (Glu182 in our model), and important non-catalytic residues shared
with all CD38 ligands: Trp125(81), Trp189(145), and Thr221(177) (Fig. 5a). This
molecule exhibited an average binding affinity of -8.81 kcal/mol, indicating the
experimental standard for endogenous ligand binding and validating the CD38
docking model. The predicted pharmacophore of NAD+, NMN+, bound CD38 with an
average affinity of -7.0 kcal/mol and demonstrated similar interactions as with NAD+
at Trp125(81), Arg127(83), Asp155/156(111/112), Trp189(145), Thr221(177), and
Glu226(182) (Fig. 5b). Kuromanin was observed to bind to the catalytic domain and
others associated with NAD+/NMN+ binding with an average affinity of -7.62
kcal/mol and no unique protein-ligand interactions (Fig. 5c). Cyanidin, the aglycone of
kuromanin, bound many of the same residues, including Glu226(182), as expected
based on their similar structures, with an average binding affinity of -7.68 kcal/mol; a
unique interaction between cyanidin and Ser(220)176 was also observed (Fig. 5d). 78c
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exhibited an average affinity of -7.42 kcal/mol, akin to those of the tested flavonoids
and endogenous ligands; however, 78c showed unique binding to Glu146(102) and an
important allosteric residue shared only with NAD+, Trp176(132) (Fig. 5e). As in a
previous study, 78c was less likely to bind Glu226(182) than the flavonoids and
endogenous ligands, possibly indicating a reduced liability for off-target binding.25
2D/3D models of 78c, kuromanin, and NAD+ reveal the differential binding patterns
of synthetic, flavonoid, and endogenous CD38 binding with the most frequently bound
residues (Fig. 6a). When forced to bind in the same pocket, metformin demonstrated
comparatively weak interactions with the most frequent residues (Fig. 6b).
Investigation of predicted targets (Table S2) and ADME characteristics (Table S1)
further facilitated the comparison of the tested CD38 inhibitors and their structural
properties. SwissTargetPrediction reported that metformin, 78c, kuromanin, cyanidin,
rutin, myricitrin, and hesperidin demonstrate respective probabilities of 0.0% (no hits),
99.1386127%, 99.9915305%, 12.2581769%, 94.879338%, 13.4155403%, and 0.0%
(no hits) for targeting CD38. SwissADME analyses revealed that 78c and cyanidin
possess structures with high drug-likeness scores, GI absorption, bioavailability, and
cell-membrane permeability as indicated by total polar surface area. Possibly related
to its lack of specificity for CD38, cyanidin and the other flavonoids possessed higher
PAINS and Brenk scores than 78c. Respectively, these calculations indicate that
cyanidin and its analogs are more likely to react nonspecifically with numerous
biological targets and have structures that are potentially reactive, metabolically
unstable, or possess properties commonly responsible for poor pharmacokinetics.33,34
Discussion
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With a validated method for hMDSC generation, various CD38 inhibitors were tested
for cytotoxicity against same-donor T cells and hMDSCs. For most test compounds,
concentrations between 10 and 100 μM resulted in a visible reduction in the viability
of both cell types (Fig. 3). Thus, to ensure the modulatory effects of these compounds
were not attributable to cytotoxicity, concentrations between 5 and 0.1 μM were
chosen for all subsequent assays. As stated earlier, a previous study measuring
recombinant CD38 inhibition by kuromanin and cyanidin observed IC50 values of 6.3
μM and 21.8 μM, respectively.24 At the time of writing, there are no reports on the
IC50 values of hesperidin, myricitrin, and rutin against CD38; the flavonoids apigenin
and quercetin have demonstrated IC50 values of 10.3-12.8 μM and 13.8-15.6 μM,
respectively, on recombinant CD38.35 Encouragingly, 78c possesses an IC50 value of
7.3 nM, implying that sufficient CD38 inhibition should occur at treatment
concentrations well below those where T cell and hMDSC cytotoxicity were observed
in this study.24
To evaluate the test compounds’ TME modulatory potential, multiplexed cytokine
analyses of media from compound-treated hMDSCs were performed. Around solid
tumors, MDSCs contribute to the generation of immunosuppressive environments by
producing various cytokines; IL-10 is one such cytokine with influence on the TME.5,6
Hence, reduced IL-10 production in hMDSCs would implicate the immunomodulatory
potential of CD38 inhibition. As demonstrated by Bunt et al. and observed in
preliminary cytokine analyses (Supplementary Fig. S4), further hMDSC activation by
LPS and IFN-γ is necessary to produce increased levels of IL-10.36 In this study,
activated hMDSCs produced far more IL-10 than those in control conditions. These
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results revealed the necessity of restimulating the generated hMDSCs to activate their
immunosuppressive mechanisms, similar to how the immune response of T cells can
be activated by stimulation with IL-2 in vitro.37 Further, treatment of activated
hMDSCs with 78c at 5 μM demonstrated reproducible IL-10 reduction. In agreement
with the previously mentioned IC50 values, kuromanin and its analogs were unable to
consistently replicate these results, presumably attributable to their comparatively
inferior potencies.
Treatment of activated hMDSCs with 78c also resulted in increased production of
MDSC-signaling cytokines, IL-1β and CCL4. A study by Yang et al. demonstrated
that high cellular NAD+ levels enhanced IL-1β release in LPS-primed human
monocytes, possibly explaining the observed IL-1β increase in response to CD38
inhibition, which is known to increase intracellular NAD+.22,25,38,39 Likewise, results
from previous studies suggest that the production of CCL4 may be a compensatory
mechanism in response to dramatic rises in cellular NAD+ caused by CD38 inhibition.
Administration of CCL4 has been found to reduce the activity of NAD-dependent
proteins, hepatic NAD+ content, and expression of NAMPT, an NAD+-producing
enzyme closely related to CD38.40–42 Through production of CCL17, MDSCs
effectively recruit Tregs to the tumor site, which subsequently generate an
immunosuppressive environment via the production of IL-10 and Foxp3.43,44 In this
study, a significant reduction in the production of CCL17 by hMDSCs was observed,
indicating that CD38 inhibition may be able to attenuate an immunosuppressive
environment in this way. MMP7, a cytokine associated with tumor size and
angiogenesis, was also significantly reduced following treatment with 78c.45,46
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In silico molecular modeling was subsequently performed on 78c, kuromanin, analogs
of kuromanin: cyanidin, hesperidin, myricitrin, and rutin, as well as endogenous CD38
ligands: NAD+ and NMN+. Kuromanin, its analogs, and the endogenous CD38 ligands
shared many of the same binding interactions, namely at the catalytic residue
Glu226(182). Specifically, NAD+ bound to Glu226(182) via its NMN+ moiety in the
same manner as NMN+ alone, suggesting that the NMN+ portion of NAD+ is largely
responsible for its binding activity at the catalytic site of CD38. These results agree
with previously published studies regarding NAD+/NMN+/flavonoid binding to
CD38.24,31
Molecular modeling showed that most of the ligands had very similar docking scores
and that all tested ligands exhibited similar binding affinities to CD38’s endogenous
ligand, NAD+. Average binding affinities for all conformations of CD38 ligands were
greater than or equal to -7.0 kcal/mol. This suggests that, with all else equal, these
molecules are capable of binding CD38 with similar affinities and any experimental
disparities are likely due to their respective ADME characteristics. Further, all
molecules shared common interactions with residues Trp125(81), Thr221(177), and
Trp189(145), possibly highlighting the major non-catalytic residues involved in CD38
binding of ligands. 78c was the only CD38 inhibitor that did not bind the catalytic
residue, Glu226(182). Additionally, it was the only ligand to bind Glu146(102) and
showed a conserved interaction with the essential allosteric residue, Trp176(132).
Considering 78c’s observed binding affinity was comparable to that of NAD+ and
inhibiting flavonoids, interactions with these residues could possibly explain the
potency disparity of 78c and flavonoids found in earlier studies.24,25 Still, the
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biorelevant models of all tested ligands revealed very similar binding affinities for
CD38. As it happens, the online SwissTargetPrediction tool indicated that 78c and
kuromanin possess extremely high and relatively similar specificity for CD38 (Table
S2). To align these findings with the respectively high and low reported IC50 values of
78c and kuromanin, one must consider the potential degradation of flavonoids in cell
culture media as well as the absorption, distribution, metabolism, and elimination
(ADME) characteristics of these compounds in vivo.34,47,48
Flavonoid-mediated CD38 inhibition remains a challenging approach due to their
extensive metabolism and liability for nonspecific targeting in vivo. As ligands for
conjugating and hydrolyzing enzymes in the small intestine/liver/colon, flavonoids
typically exhibit low oral bioavailability.49,50 While intravenous administration is
possible, enzymatic saturation can improve gut absorption, and the products of
metabolism may retain bioactivity, these properties paint flavonoids as unattractive
candidates for drug development. Further, previous docking studies suggest that the
most potent flavonoid inhibitor of CD38, luteolinidin, mimics the interaction of the
NMN+ moiety of NAD+ in CD38’s active site. Considering the molecular docking and
SwissTargetPrediction results in this study, it is likely that all flavonoids inhibit CD38
activity by mimicking NMN+ in a similar way.24 Because NAD+ is a ligand for a wide
variety of receptors, catalytic inhibitors like NAD+ analogs and flavonoids are less
likely to specifically target CD38 and therefore more likely to produce unwanted side
effects.39,51–55 Notably, cyanidin has been previously implicated in the treatment of
rheumatoid arthritis by suppressing CD38+ NK cells and inducing Tregs.56
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Our results from in silico analyses comparing the ADME characteristics of 78c and the
tested flavonoid inhibitors support findings from the aforementioned studies,
highlighting 78c’s superior gastrointestinal absorption, cell-membrane permeability as
indicated by total polar surface area, and drug likeness qualities (all calculated by
SwissADME). Also in agreement with these calculations, a previously mentioned
study investigating anti-CD38 therapies in chronic lymphocytic leukemia models
concluded that kuromanin is a weak CD38 enzymatic inhibitor in vivo, relative to 78c,
and that future experiments should use the latter.21 In comparison to its synthetic
analogs, 78c has demonstrated superior CD38 inhibition (measured by NAD+ levels),
clearance values, half-life, volume of distribution, and oral bioavailability in mice.
Interestingly, the study reported enhanced NAD+-elevating effects by 78c in the liver
as opposed to gastrocnemius tissue, indicating a potential advantage for targeting
TMEs located in the liver.25 Considering overexpression of CD38 was observed in
MDSCs taken from murine liver metastases, the observed organ-specific targeting by
78c suggests increased utility in the immunomodulation of liver TMEs.10
It is worth noting that, while expensive, monoclonal antibodies (e.g., daratumumab)
promise highly specific targeting of CD38.19,20 However, the comparatively low cost
of small molecules constitutes an attractive trait for coadministration studies when
considering the high costs associated with adoptive T-cell therapies.57
While the results of this study demonstrate the immunomodulatory potential of CD38
inhibition in hMDSCs, further studies will be necessary to confirm its potential for
enhancing immunotherapies. This investigation highlights experimental limitations
that future studies should account for: The first is donor variability - more biological
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replicates will be needed if hMDSC samples are being generated in vitro from donor
PBMCs. The second is lack of material for MS-based proteomics – the small-scale
nature of the assays in this study lead to difficulties in MS-based proteomic analysis of
tested samples. Future validation studies should be conducted in biosystems of
increased complexity. Previously, several studies have reported on the culturing of
immune cells in the presence of tumor spheroids;58–61 integration of these techniques
introduces a new way of modeling the TME and validating targets therein. By
generating an environment that more closely resembles the physiology associated with
in vivo models, microfluidic platforms offer a way to further improve the validity of
these preclinical evaluations.62,63 In these and traditional in vivo models, cytokine
production, tumor size/viability, T cell vs MDSC infiltration, and differential gene
expression can be measured to validate the findings of this report.
In this study, results from cell-based assays revealed a common range of
concentrations that were cytotoxic to T cells and hMDSCs as well as the
immunomodulatory actions of 78c on hMDSCs stimulated with LPS and IFN-γ.
Specifically, treatment of hMDSCs with 78c effectively reduced the extracellular
presence of IL-10, CCL17, and MMP7 while inducing a compensatory production of
IL-1β and CCL4. Considering the respective roles these cytokines play in the TME,
CD38 inhibition may influence the generation of a less immunosuppressive
environment to maximize the efficacy of cell-based immunotherapies.
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Tables
Donor

Differentiation Method

Experiment(s)

+

1

Day 0: isolated CD3 T cells

2

Day 0: isolated CD3+ T cells and stimulated with
20 ng/mL IL-2; stimulated remaining PBMCs
with 5 μg/mL PGE-2, 500 ng/mL GM-CSF, and
200 ng/mL IL-6

CellTiter-Glo 2.0 Cell Viability Assay
(Fig. S3)
CellTiter-Glo 2.0 Cell Viability Assay
(Figure 3a)

Day 4: restimulated 1 μg/mL PGE-2, 100 ng/mL
GM-CSF, and 40 ng/mL IL-6
Day 5: harvested CD33+ hMDSCs
Same as above

✝

5

Same as above

✝

Cytokine analysis (IL-10) (Fig. S4a)

6

*(Stimulated with 100 ng/mL IFN-γ for hMDSCactivation and treated with test compounds)
Same as above

Cytokine analysis (IL-10) (Fig. S4b)

7

*(Stimulated with 100 ng/mL IFN-γ and 200
ng/mL LPS for hMDSC-activation and treated
with test compounds)
Same as above
*(Stimulated with 50 ng/mL IFN-γ and 100
ng/mL LPS for hMDSC-activation and treated
with test compounds)

3/4

✝

✝

Proteomic comparisons (SWATH-MS)
Proteomic comparisons (SWATH-MS)

Proteomic comparisons (SWATH-MS)

Proteomic comparisons (SWATH-MS)

8

Same as above

Multiplexed cytokine analysis (IL-10,
IL-12(p70), IL-13, IL-17A, IL-15,
CCL2, CCL4, CCL17, TNFα, IL-1β)
(Figs. 4, S5)
✝
Proteomic comparisons (SWATH-MS)

9

*(Stimulated with 75 ng/mL IFN-γ and 150
ng/mL LPS for hMDSC-activation and treated
with test compounds)
Same as above

Multiplexed cytokine analysis (IL-10,
TNFα, IL-1β, IL-8; MMP7, MMP9,
MPO) (Figs. 4, S6)
Cytokine analysis (IL-10) (Fig. S7a)

*Day 0: 100 ng/mL GM-CSF, 100 ng/mL IL-6
*Day 4: 100 ng/mL IL-6

10

(Stimulated with 75 ng/mL IFN-γ and 150 ng/mL
LPS for hMDSC-activation and treated with test
compounds)
Same as above

11

Same as above

CellTiter-Glo 2.0 Cell Viability Assay
(Fig. 3b-g)
Cytokine analysis (IL-10) (Fig. S7b)
✝
Proteomic comparisons (SWATH-MS)

*(Stimulated with 75 ng/mL IFN-γ and 150
ng/mL LPS for hMDSC-activation and treated
with test compounds)
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*Variation in method
✝
Data not shown

Table 1. List of donors - their respective differentiation methods and experiments

60

Figures

Figure 1. Theorized modulation of MDSC cytokine production via CD38
inhibition (78c). hMDSCs suppress cytotoxic T cells, such as those engineered in
CAR T-cell therapy, primarily through an upregulated secretion of IL-10. However,
cytokines such as CCL17, IL-17A, TGF-β, Arg1, etc. are also implicated in hMDSCmediated immunosuppression.3,5,6 Thus, small-molecule modulation of these
secretions may result in a less suppressive TME and support the success of
immunotherapies.
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Figure 2. Chemical structures of CD38 inhibitors screened for TME modulatory
effects.

62

Figure 3. CD38 inhibitors exhibit varying degrees of cytotoxicity in CD3+ T cells
and CD33+ hMSDCs after 24 h. Cells from Donor 2 were treated with (A) 78c and
kuromanin (not shown) at multiple doses (n = 4). Repeated with Donor 10, (B)
kuromanin and its analogs: (C) cyanidin, (D) hesperidin, (E) myricitrin, and (F) rutin
63

were tested at similar doses (n = 3). (G) With the exception of hesperidin, the
flavonoids showed low IC50 values on T cells and hMDSCs. A dashed line at 70%
serves as a viability cutoff, thus sample averages >70% are presumed to be healthy.
Data was plotted as mean values ± SD.
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Figure 4. CD38 inhibitor, 78c, modulates key immunomodulatory cytokines in
vitro. Data shown includes results for two donors; hMDSCs from Donor 12 were
measured for (A) IL-10, (B) IL-1β, (C) CCL4, (D) CCL17 production in response to
treatment with 78c at 5 μM, 1 μM, and 0.1 μM (most not shown) in the presence of
LPS (150 ng/mL) and IFN-γ (75 ng/mL) (n = 4). hMDSCs from Donor 13 were
measured for (E) IL-10 and (F) MMP7 production in response to treatment with 78c at
65

5 μM and 1 μM, also in the presence of LPS and IFN-γ (n = 4). DMSO-treated (0.1%)
hMDSCs, as well as untreated cells, serve as control for this experiment. Data was
plotted as mean values ± SD and statistically significant results are indicated by P
values analyzed by one-way ANOVA analysis, * P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001
**** P ≤ 0.0001.
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Figure 5. Top-scoring conformations of test ligands in complex with CD38 shared
protein-ligand interactions with Trp125(81), Thr221(177), and Trp189(145). As
described by Haffner et al, (E) 78c was the only ligand that did not bind to the
catalytic residue of CD38, Glu226(182), and the only one to bind Glu146(102).
Besides (A) NAD+, 78c was the only one to bind Trp176(132). Interactions with
Glu146 and Trp176 likely play a role in the in vivo potency of 78c whilst avoiding the
catalytic domain altogether, possibly reducing its liability for targeting other NAD+consuming enzymes.
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Figure 6. Overlaid docking of CD38 ligands and metformin reveal binding
patterns for enzymatic inhibition. (A) 78c (cyan), kuromanin (gray), and NAD+
(red) conformations are shown complexed with CD38. Also shown: the catalytic
domain (orange), amino acids bound by all CD38 ligands (green) and those bound
only by 78c (blue). (B) A 3D model of metformin’s top nine conformers forced to
dock near the enzymatic residue of CD38 and a 2D model of the weak interactions
observed in the top conformer.
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Supplementary Tables
Physiochemical Properties
Compound Name

Formula

Molecular Weight

H-bond acceptors

H-bond donors

TPSA

78c

C22H27N3O3S

413.53

4

1

93.62

Kuromanin

C21H21ClO11

484.84

11

8

193.44

Cyanidin

C15H11ClO6

322.7

6

5

114.29

Rutin

C27H30O16

610.52

16

10

269.43

Myricitrin

C21H20O12

464.38

12

8

210.51

Hesperidin

C28H34O15

610.56

15

8

234.29

Consensus Log P

Lipophilicity
Compound Name

iLOGP

WLOGP

XLOGP3

78c

3.89

3.86

2.95

3.36

Kuromanin

-4.82

-2.61

0.94

-1.99

Cyanidin

-4.55

-0.09

1.57

-0.45

Rutin

2.43

-1.69

-0.33

-1.12

Myricitrin

0.92

0.19

0.51

-0.23

Hesperidin

2.6

-1.48

-0.14

-0.72

Water Solubility
Compound Name

Log S (ESOL)

Class (ESOL)

Log S (Ali)

Class (Ali)

Log S (Silicos-IT)

Class (Silicos-IT)

78c

-4.18

Moderately soluble

-4.58

Moderately soluble

-6.43

Poorly soluble

Kuromanin

-3.53

Soluble

-4.59

Moderately soluble

-0.93

Soluble

Cyanidin

-3.3

Soluble

-3.58

Soluble

-2.66

Soluble

Rutin

-3.3

Soluble

-4.87

Moderately soluble

-0.29

Soluble

Myricitrin

-3.2

Soluble

-4.5

Moderately soluble

-1.49

Soluble

Hesperidin

-3.28

Soluble

-4.33

Moderately soluble

-0.58

Soluble

Drug Likeness
Compound Name

Lipinski

Ghose

Veber

Egan

Muegge

Bioavailability
Score

78c

Yes; 0 violations

Yes; 0 violations

Yes

Yes

Yes

0.55

Kuromanin

No; 2 violations

No; 2 violations

No; 1 violation

No; 1 violation

No; 3 violations

0.17

Cyanidin

Yes; 0 violations

Yes; 0 violations

Yes

Yes

Yes

0.55

Rutin

No; 3 violations

No; 4 violations

No; 1 violation

No; 1 violation

No; 4 violations

0.17

Myricitrin

No; 2 violations

Yes; 0 violations

No; 1 violation

No; 1 violation

No; 3 violations

0.17

Hesperidin

No; 3 violations

No; 4 violations

No; 1 violation

No; 1 violation

No; 4 violations

0.17

Med Chem
Compound Name

PAINS

Brenk

Leadlikeness

Synthetic
Accessibility
4.17

78c

0 alerts

0 alerts

1

Kuromanin

1 alert

2 alerts

1

5.3

Cyanidin

1 alert

2 alerts

0

3.18

Rutin

1 alert

1 alert

1

6.52

Myricitrin

1 alert

1 alert

1

5.32

Hesperidin

0 alerts

0 alerts

1

6.34

Pharmacokinetics
Compound Name

GI absorption

BBB permeant

Pgp substrate

# CYPs inhibited

78c

High

No

Yes

4

Kuromanin

Low

No

No

0

Cyanidin

High

No

Yes

0

Rutin

Low

No

Yes

0

Myricitrin

Low

No

No

0

Hesperidin

Low

No

Yes

0

Table S1. In silico analysis by SwissADME highlights drug-like properties of 78c
in comparison to kuromanin and its analogs. 78c possesses a structure with a
70

favorable structure for drug development, as determined by a number of tests using
various algorithms for identifying drug-like properties in molecules. It is not likely to
react nonspecifically in bioassays or possesses properties responsible for poor
pharmacokinetics. These results agree with a previously published study on its
pharmacokinetic properties in a murine model.25 Cyanidin was found to share many of
these properties but remains liable for nonspecific targeting and extensive metabolism
(Scalbert et al., 2002; Thilakarathna & Rupasinghe, 2013).49,50 Results are
conditionally formatted to highlight, in green, characteristics associated with optimal
parameters for candidates of drug development.
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Compound Name

Target (common name) Probability (0.0 - 1.0)

Metformin (Control) CD38

0.0 (no hits)

NAD(+)

CD38

0.074564954

78c

CD38

0.991386127

Kuromanin

CD38

0.999915305

Cyanidin

CD38

0.122581769

Rutin

CD38

0.094879338

Myricitrin

CD38

0.134155403

Hesperidin

CD38

0.0 (no hits)

Table S2. In silico analysis by SwissTargetPrediction emphasizes the superior
biochemical specificity of kuromanin and 78c for CD38. Contrary to its structural
similarity to the other flavonoids, hesperidin was predicted to have a 0% chance of
binding to CD38 in vivo; a lack of published studies on this hesperidin’s CD38targeting capability may be responsible for this result.
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Supplementary Figures

Figure S1. Structures of endogenous CD38 ligands, NAD+, and its precursor
molecule, NMN+, also screened in the molecular docking study as functional
controls for catalytic-site binding.
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Figure S2. Docking scores of top CD38-ligand conformations indicate similar
binding affinities for all tested molecules and a clear separation from the negative
control, metformin. While the endogenous ligand, NAD+, expressed the greatest
affinity for CD38, the difference in docking scores is negligible and subject to small
error. The mean score values ± SD for the top nine conformations (Exhaustiveness:
50) are shown. Statistically significant results are indicated by P values analyzed by
one-way ANOVA analysis, **** P ≤ 0.0001.
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Figure S3. Cytotoxicity of Kuromanin and 78c in CD3+ T cells after 24 h. T cells
from Donor 1 were treated with kuromanin and 78c at multiple doses (n = 2); IC50
values were both >100 µM. A dashed line at 70% serves as a viability cutoff, thus
sample averages >70% are presumed to be healthy. Data was plotted as mean values ±
SD.
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Figure S4. Results from preliminary ELISA assays measuring IL-10 production
in hMDSCs. (A) hMDSCs from Donor 5 were stimulated with 50 ng/mL IFN-γ and
simultaneously treated with CD38 inhibitors, kuromanin and 78c, at 1 µM and 1-5 µM
for 6 and 18 h, respectively. Pre-stimulation of hMDSCs with LPS and IFN-γ
augmented pro-inflammatory cytokine secretion. (B) hMDSCs from Donor 6 were
either stimulated with 500 ng/mL LPS and 100 ng/mL IFN-γ followed by 0.1-5 µM or
not stimulated at all and treated with 1-5 µM for 24 h. An oversaturated IL-10 signal
was observed, indicating the need for reduced LPS and IFN-γ stimulation.
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Figure S5. Results from multiplexed cytokine analysis of hMDSCs from Donor 7
after 24 h. Samples were measured for the production of various cytokines in
response to treatment with 78c at 5 μM, 1 μM, and 0.1 μM (most not shown) in the
presence of LPS (150 ng/mL) and IFN-γ (75 ng/mL) (n = 4). Data was plotted as mean
values ± SD and statistically significant results are indicated by P values analyzed by
one-way ANOVA analysis, * P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001.
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Figure S6. Results from multiplexed cytokine analysis of hMDSCs from Donor 8
after 24 h. Samples were measured for the production of various cytokines in response
to treatment with 78c at 5 μM and 1 μM, also in the presence of LPS and IFN-γ (n = 4).
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DMSO-treated (0.1%) hMDSCs were used as vehicle samples and untreated cells were
used as controls. Data was plotted as mean values ± SD and statistically significant
results are indicated by P values analyzed by one-way ANOVA analysis, * P ≤ 0.05 **
P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001.
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Figure S7. Kuromanin and its analogs demonstrate inconsistent modulation of
IL-10 production after 24 h. (A) In Donor 9 ignificant IL-10 reduction was seen for
all compounds, except for cyanidin. However, when the experiment was repeated with
Donor 10 (B) no significant IL-10 reduction was observed. For both experiments,
samples were run in quadruplicate with DMSO-treated (0.1%) hMDSCs serving as the
experimental control. All other samples were stimulated with LPS and IFN-γ before
treatment with test compounds, concentrated at either 5 μM or 1 μM. Data was plotted
as mean values ± SD and statistically significant results are indicated by P values
analyzed by one-way ANOVA analysis, * P ≤ 0.05 *** P ≤ 0.001 **** P ≤ 0.0001.
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CHAPTER 3
This manuscript will be submitted for publication in BMC Journal of Translational
Medicine: Cancer Microenvironment. The formatting follows the guidelines set forth
by the journal.
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Abstract
With increasing clinical successes, adoptive T-cell immunotherapy represents one of
the most exciting treatments for hematological malignancies (e.g., leukemia, lymphoma,
etc.). However, immunotherapy efficacies have been difficult to replicate in the
treatment of solid tumors, owing to the immunosuppressive nature of cells in the tumor
microenvironment (TME). Myeloid-derived suppressor cells (MDSCs) in the TME
produce cytokines that mitigate the attack of T cells against the tumor. Recent studies
have shown that Wnt-pathway triggering protein, β-catenin, is associated with the
MDSC populations within murine lung metastases. Considering the role of the Wnt/βcatenin pathway in immune cell communication and function, modulation of this protein
and other points in its associated pathway may offer an opportunity for reducing MDSCmediated suppression of immune cells. In this study, we determined the cytotoxic ranges
of small molecule Wnt/β-catenin inhibitors against MDSCs differentiated from the
PBMCs of healthy human donors (hMDSCs) and their autologous T cells. Due to
favorable toxicity profiles, the investigative drugs FH535 and ICRT14 were further
evaluated for their influence on key immunomodulatory cytokines in hMDSCs.
Treatment of hMDSCs with FH535 resulted in a 70% decrease or more in their
production of immunosuppressive IL-10 while ICRT14 induced a 142% increase in
CCL4 and a 46% decrease in produced CCL17. In one instance, treatment of hMDSCs
with ICRT14 also caused a 43% decrease of IL-1β. Finally, in silico analysis was used
to predict the physiological parameters and absorption, distribution, metabolism, and
elimination (ADME) characteristics of test compounds. Based on these findings, both

84

FH535 and ICRT14 demonstrate attributes that encourage further evaluation in the
context of improving immunotherapy outcomes in solid tumors.
Introduction
Various forms of immunotherapy have seen success in the treatment of blood-based
cancers, but success in solid tumors has been limited due to the immunosuppressive
nature of the TME.1 As researchers explore ways to maximize the efficacy of
immunotherapy, modulation of tumor-protective immune suppressor cells is an
attractive strategy.2 While there are several types of immune suppressor cells, MDSCs
have been reported to directly suppress the activity of T cells, dendritic cells, and
macrophages by secreting IL‐10, arginase 1 (Arg1), nitric oxide (NO), transforming
growth factor (TGF)‐β, and cyclooxygenase (COX)-2.3,4 Moreover, these cytokines can
induce the recruitment of Tregs and tumor-associated macrophages (TAMs) to the
TME.5,6 Therefore, discovery and validation of MDSC-associated targets for
immunomodulation should be prioritized for future development of therapeutic agents.
One potential target, β-catenin, was reported following proteomic analysis of MDSCs
from murine lung metastases.7–9 Encoded by the human gene, CTNNB1, β-catenin is a
cytoplasmic protein necessary for the transcription of Wnt-associated genes. The Wntβ-catenin pathway is important for cell communication, cell–cell adhesion, and other
functions for cellular homeostasis.10,11 In the context of tumorigenesis, unregulated
Wnt-signaling appears to contribute to immune evasion, tumor progression, and
resistance to immunotherapeutic treatment.12 Most notably, activation of this pathway
can decrease the efficacy of anti-PD-1 immunotherapy in mice, likely due to an
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upregulation of IL-10 in the TME resulting in diminished T cell activity and increased
MDSC recruitment.13,14 Moreover, studies of melanoma and tetronoma models have
correlated activation of the Wnt/β-catenin pathway with the absence of a T-cell gene
expression signature and reduced CTL infiltration.15,16
At time of writing, little is known about the efficacy of Wnt-β-catenin inhibitors for the
purpose of MDSC immunomodulation. There are, however, compounds capable of
inhibiting this pathway in a variety of ways. Mechanisms may involve augmentation of
β-catenin degradation, prevention of its nuclear translocation, or by inhibition of
protein-serine O-palmitoleoyltransferase (PORCN) to decrease production of Wnt
ligands.12,17 A visualization of these mechanisms and chemical structures of their
associated Wnt/β-catenin inhibitors can be found in Figures 1 and 2, respectively.
ICRT14 exerts its effect by inhibiting the association of β-catenin with TCF4/LEF
transcription factors to prevent the transcription of Wnt-associated genes.18 A PORCN
inhibitor, ETC-159 blocks the secretion of Wnt ligands which would initiate Wnt
expression.19 MSAB is an inhibitor shown to bind primarily to β-catenin itself, likely
inducing conformational changes that diminish its function.20 IWR1, a tankyrase
inhibitor, preserves crucial β-catenin destruction complex proteins to block
translocation of β-catenin into the nucleus.21 CCT251545 targets the Mediator complex
by selectively binding protein kinases, CDK8 and CDK1, effectively suppressing
pathway expression.22 FH535 uniquely prevents β-catenin degradation by cytosolic
peroxisome proliferator-activated receptors (PPARs) yet directly blocks β-catenin
binding for TCF4/LEF-mediated Wnt gene transcription.23 Lastly, natural product
salinomycin inhibits ligand binding of membranous Wnt coreceptor, lipoprotein
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receptor related protein 6 (LRP6).24,25 Studies of such inhibitors in the context of
targeting MDSCs could provide clues for developing therapeutic agents that modulate
the TME.
In this study, previously reported methods for hMDSCs differentiation from healthy
donors were used to investigate the cytotoxic and immunomodulatory effects of these
β-catenin inhibitors.6,26 Implications of experimental observations are discussed,
considering the potential causes and downstream impacts of β-catenin inhibition on the
TME. Results from an in silico evaluation of inhibitor ADME characteristics are also
discussed in the context of existing experimental data to generate a drug development
framework for improving the outcomes of adoptive T-cell therapies.
Materials and methods
Differentiation of donor PBMCs to CD33+ hMDSCs
Healthy human donor apheresis chambers (LRS) were obtained from the Rhode Island
Blood Center (Providence, RI). Qualified donors were required to be between the ages
of 18-50 yr with no preexisting health conditions or use of immunosuppressive drugs.
PBMCs were isolated using ficoll-paque (Cytiva, Marlborough MA) density gradient
centrifugation according to Cytiva’s procedures. Briefly, contents were transferred onto
15 mL Ficoll-Paque Plus in 50 mL tubes for centrifugation in an Eppendorf 5804R
(Eppendorf, Hamburg, Germany) at 1700 rpm for 30 min with low acceleration and no
brake. To obtain PBMCs, Ficoll-separated monocytes were aspirated using 10 mL
serological pipettes and washed in a separate 50 mL tube by centrifuging at 1700 rpm
for 7 min. PBMCs were then counted using trypan blue dye exclusion on a Nexcelom
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Cellometer before separating for T cells using dextran coated magnetic bead separation
(StemCell Technologies, Vancouver, Canada). T cells were then cultured in T75 flasks
at a density of 5x106 cells/mL with ImmunoCult™-XF T Cell Expansion Medium
(StemCell Technologies).
Negative cells were placed into T75 flasks at a density of 5x106 cells/mL and cultured
as described by Tomić et al. to generate human MDSCs.26 Specifically, RPMI1640
Media (Life Technologies, Waltham, MA) was supplemented with 10% Fetal Bovine
Serum (FBS) (Life Technologies), 1% Penicillin/Streptomycin (Life Technologies), and
a combination of IL-6 (Biolegend, San Diego, CA), GM-CSF (Biolegend), and
Prostaglandin E2 (PGE2, R&D Systems, Minneapolis, MN) for 3-7 days. hMDSCs
were isolated from the harvested cells using a CD33+ immunomagnetic positive
selection kit (StemCell Technologies) according to the manufacturer’s protocol.
Cell viability assay for evaluation of compound cytotoxicity on hMDSCs and T
cells.
Wnt/β-catenin inhibitors ICRT14, ETC-159, MSAB, IWR-1, CCT251545, FH535 and
salinomycin (all from MedChemExpress LLC, Monmouth Junction, NJ) were evaluated
for cytotoxicity against hMDSCs and T cells. The respective cell types were added to
wells at 5x105 cells/mL in white-walled 96-well plates and treated with compounds at
concentrations ranging between 100, 10, 1, 0.1, 0.01, and 0.001 µM, or were treated
with 0.1% DMSO (vehicle control). After 24 h, CellTiter-Glo 2.0 Cell Viability kits
(Promega, Madison, WI) were used according to manufacturer protocol to measure the
presence of ATP in response to compound treatment. Briefly, 100 µL CellTiter-Glo 2.0
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reagent was added to wells with 100 µL cell media; luminescence was recorded on a
SpectraMax ID3 Plate Reader (Molecular Devices, San Jose, CA) and cell viability was
analyzed on GraphPad with DMSO controls representing 100% cell viability.
MDSC stimulation and cytokine analysis
CD33+ MDSCs were seeded in 48-well plates at a density of 1x106 cells/mL.
Lipopolysaccharide (LPS, Sigma Aldrich) and interferon-gamma (IFN-γ, Biolegend)
were added concomitantly with vehicle (DMSO, 0.1% v/v), with or without compound
(5, 1, and 0.1 µM), and incubated for 24 h. Cell culture media was then collected and
stored at -80°C for cytokine analysis. Media was initially analyzed for IL-10 content by
ELISA according to manufacturer (Biolegend) instructions and using manufacturer
supplied reagents. Media was also profiled for the production of other cytokines using
three different panels for multiplexed analysis (IL-10, IL-12(p70), IL-13, IL-17A, IL15, CCL2, CCL4, CCL17, TNFα, IL-1β; IL-10, TNFα, IL-1β, IL-8; MMP7, MMP9,
MPO) on an Ella cytokine multiplexing instrument (Protein Simple, San Jose, CA)
according to the manufacturer’s protocol for Simple Plex Assays.
Data Analysis
Cytotoxicity, ELISA, and multiplex data were analyzed using Graphpad Prism (Ver 9,
La Jolla, CA) statistical software. Comparisons between ELISA and multiplex samples
were performed by paired t-tests or one-way analysis of variance (ANOVA) where
appropriate, and statistical significance was determined as * P ≤ 0.05 ** P ≤ 0.01 *** P
≤ 0.001 **** P ≤ 0.0001.
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In silico drug-likeness analysis and target prediction of Wnt/β-catenin inhibitors
The SMILES data for known Wnt/β-catenin inhibitors were entered into the opensource program, SwissADME (http://www.swissadme.ch/) to predict key physiological
parameters such as lipophilicity, synthetic accessibility, likelihood to permeate cell
membranes, and overall lead likeness (Table 2).
Results
Differentiation of donor PBMCs to CD33+ hMDSCs
All donor PBMCs were processed in accordance with their intended applications
following differentiation. These applications included CellTiter-Glo viability assays,
various immunosorbent assays, and total protein analyses using Sequential Window
Acquisition of All Theoretical Mass Spectra (SWATH-MS) (data not shown). Because
each donor was used for investigating different endpoints, their appearance in the
following sections are not chronological; for reference, their respective differentiation
methods and subsequent experimental applications can be found in Table 1.
Evaluation of cytotoxicity on hMDSCs and T cells by Wnt/β-catenin inhibitors
T cells and hMDSCs from three donors were used to evaluate the cytotoxic effects of
selected test compounds. In Donor 1, treatment with ICRT14 resulted in calculated IC50
values of >100 μM and 52.17 μM for T cells and hMDSCs, respectively (Fig. 3a, h).
ETC-159, MSAB, IWR-1, and CCT251545 were tested on cells from Donor 8, all
exhibiting IC50 values >100 μM except for MSAB (hMDSCs: 10.92 μM) (Fig. 3b-e, h).
The calculated IC50 values of cells from Donor 9 treated with FH535 (T cells: 1.16 μM;
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hMDSCs: 6.36 μM) and salinomycin (T cells: 3.99 μM; hMDSCs: 4.49 μM) indicate
that these test compounds may possess unfavorable toxicity profiles, capable of exerting
cytotoxicity at concentrations used in subsequent assays (Fig. 3f-h). To induce hMDSCs
modulation while minimizing significant reductions in cell viability, compound
concentrations of 5, 1, and 0.1 µM were selected for cytokine analyses. Notably, all
compounds induced proliferation of T cells at one or more of the tested concentrations,
resulting in viabilities greater than 100% (Fig. 3a-g).
Stimulation with IFN-γ and LPS needed to induce immunosuppressive hMDSC
phenotype
IL-10 production by Donor 4 hMDSCs was measured by ELISA in response to ICRT14
treatment, with or without the initial cell exposure to 50 ng/mL IFN-γ for 6 or 24 h.
Results from all doses and timepoints in this experiment indicated that the CD33+
(pre-)hMDSC model required further inflammatory stimulation to increase IL-10
production (Supplementary Fig. S1). Stimulation of hMDSCs from Donor 5 with 500
ng/mL LPS and 100 ng/mL IFN-γ directly before treatment with the test compounds led
to a saturation in the IL-10 (data not shown). Therefore, inflammatory stimulation of
hMDSCs was decreased to 150 ng/mL LPS and 75 ng/mL IFN-γ.
Modulation of hMDSC cytokine release by β-catenin inhibitors
Treatment of hMDSCs from Donor 6 with ICRT14 at 5 and 1 μM induced 142% and
158% increases, respectively, in CCL4 signal (Fig. 4a). At the same time, production of
CCL17 and IL-1β was reduced by 46% and 43%, respectively, upon treatment with
ICRT14 at 5 μM (Fig. 4b, c). Interestingly, the reductions were observed regardless of
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if the hMDSCs were stimulated with LPS/IFN-stimulated. A separate analyte panel on
hMDSCs from Donor 7 was unable to reproduce the observed reduction of IL-1β signal
in response to ICRT14 at both 5 and 1 μM (Fig. 4d). No significant modulations of other
measured cytokines (IL-12(p70), IL-10, IL-13, IL-17A, IL-15, CCL2, TNFα, IL-8,
MMP7, MMP9, MPO) were observed following treatment with ICRT14
(Supplementary Figs. S2a-f, i and S3a, c-g). In comparison, Wnt/β-catenin inhibitors
FH535 and salinomycin both demonstrated reductions of IL-10 by more than 70% in
hMDSCs from Donor 8 treated at 1 and 5 µM, respectively (Fig. 4e). Repeated with
Donor 9, only FH535 induced 70% and 64% reductions of IL-10 signal at both 5 and 1
µM, respectively (Fig. 4f).
In silico ADME analysis of tested Wnt/β-catenin pathway inhibitors
Investigation of predicted ADME characteristics further facilitated the comparison of
the tested Wnt/β-catenin inhibitors and their structural properties. SwissADME analysis
revealed that the consensus logP values of inhibitors ICRT14, ETC-159, MSAB, IWR1, CCT251545, FH535, and salinomycin were 3.52, 0.98, 2.61, 3.11, 3.07, 2.86, and
5.00 respectively. These values suggest that their structures are relatively lipophilic,
indicating high membrane permeability. Total polar surface area (TPSA) values of
synthetic inhibitors ICRT14 (80.5 Å), ETC-159 (116.7 Å), MSAB (80.85 Å), IWR-1
(79.37 Å), CCT251545 (63.05 Å), and FH535 (100.37 Å) fall below a threshold of 120
Å, implying favorable TPSA for oral absorption. With a high molecular weight (751.0
g/mol), salinomycin showed unfavorable drug-likeness scores, GI absorption, and
bioavailability cell-membrane permeability as indicated by TPSA. Relative to most
natural products, salinomycin received low PAINS and Brenk scores, indicating that it
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is less likely to react nonspecifically with biological targets and has a low potential for
being reactive, metabolically unstable, or possessing poor pharmacokinetics.27 Most
synthetic Wnt/β-catenin inhibitors received favorable scores in these categories as well,
indicating reasonable leadlikeness for all test compounds. Salinomycin was predicted
to modulate only one cytochrome P450 (CYP) enzyme, less than most of the synthetic
inhibitors, and is not a substrate for permeability-glycoprotein (Pgp). ICRT14 and
FH535, on the other hand, were predicted to inhibit four CYP enzymes with no Pgp
interaction. A conditionally formatted list of predicted ADME characteristics for all
tested Wnt/β-catenin inhibitors can be found in Table 2.
Discussion
Various Wnt/β-catenin inhibitors were tested for cytotoxicity against same-donor T
cells and hMDSCs. For most test compounds, concentrations above 10 μM resulted in
a visible reduction in the viability of both cell types (Fig. 3). Thus, to ensure the
immunomodulatory effects of these compounds were not attributable to cytotoxicity,
concentrations between 5 and 0.1 μM were chosen for all subsequent assays. Though
FH535 and salinomycin exerted the highest cytotoxic effects in this study, both have
been reported to spare PBMCs at doses greater than 10 μM while selectively targeting
cancer cells.28,29 Similarly, MSAB exerted preferential cytotoxicity in Wnt-dependent
cancer cells, but not in normal human cells.20 ICRT14 was moderately toxic to T cells
in this study but has also been shown to spare Wnt-independent cell lines at doses
greater than is required for effective Wnt inhibition.30,31 Limited cytotoxicity was
observed in cells treated with CCT251545 below 10 μM, but evaluation of its toxicity
in vivo has revealed toxic effects on multiple organ systems at Wnt-inhibiting doses.32
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By contrast, ETC-159 has been reported to inhibit Wnt signaling in a clinical trial at
doses tolerable for human.33 IWR-1, showing low cytotoxic activity in this study, has
also been evaluated for Wnt/β-catenin inhibition in vitro at concentrations as high as 10
μM.
To evaluate immunomodulatory potential, cytokine analyses of media from compoundtreated hMDSCs were performed. In the context of solid tumors, MDSCs suppress the
activity of otherwise active immune cells by producing various cytokines; production
and secretion of IL-10 is one mechanism by which MDSCs achieve this effect.3,4 Hence,
reduced IL-10 production in hMDSCs may indicate a compound’s immunomodulatory
effect, warranting further investigation. As demonstrated by Bunt et al. and observed in
preliminary cytokine analyses (Supplementary Fig. S1), production of IL-10 by
hMDSCs is potentiated by in vitro stimulation with LPS and IFN-γ.34 Likewise,
expression of immunomodulatory cytokines IL-1β, TNFα, CCL4, and MMP7 were
enhanced upon inflammatory stimulation. These results demonstrate the necessity of
restimulating donor hMDSCs for activating their immunosuppressive mechanisms,
similar to their initial differentiation with PGE-2/GM-CSF/IL-6 and how T cells can be
activated by stimulation with IL-2 in vitro.35
The Wnt/β-catenin pathway can be activated by Wnt ligands released by tumor cells,
effectively increasing the production of IL-10 and other immunosuppressive cytokines
in dendritic cells (DCs) and Tregs.36–38 In our study, treatment of hMDSCs with FH535
resulted in repeated impediment of IL-10 production, suggesting that the compound’s
unique dual inhibition of the Wnt/β-catenin pathway and PPARs could be responsible
for the observed results. Indeed, PPARγ has been implicated in the anti-inflammatory
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role of MDSCs by diminishing production of pro-inflammatory cytokines.23,39 By
contrast, salinomycin was unable to induce reproducible IL-10 reductions; considering
their similar potencies for Wnt-inhibition as demonstrated in earlier studies, this
disparity is especially interesting and likely due to variations in mechanism of
action.24,40 Thus, more studies exploring the immunomodulatory influence of FH535’s
unique mechanism will aid in evaluating its potential for the reversal of MDSCmediated immunosuppression.
Though not capable of reducing IL-10, treatment of hMDSCs with ICRT14 reduced
production of CCL17 and IL-1β while increasing production of CCL4. One mechanism
by which MDSCs generate an immunosuppressive environment is by production of
CCL17 for recruitment of Tregs to the tumor site, which produce immunosuppressive
IL-10 and Foxp3.41,42 Early studies have implicated IL-1β in MDSC accumulation,
where its overexpression metastatic models lead to increased MDSCs recruitment and
its inhibition suppresses MDSC reverses this effect and obstructs tumor development in
this manner.43 Other consequences of upregulated IL-1β production include decreased
NK cell functionality and increased tumor growth, likely in response to IL-1β-induced
IL-10 production.34,44 Upregulation of the Wnt/β-catenin pathway is associated with
decreased CCL4 levels in MDSCs, thus the observed increase in CCL4 may represent
successful inhibition of this pathway. Production of CCL4 by MDSCs has been shown
to increase suppressor-cell migration and reduce infiltration of immune cells into the
tumor.45 Interestingly, rescue of downstream Wnt expression in MDSCs by anti-Dkk1
treatment prevents tumor growth by reducing MDSC recruitment to the tumor site,
restoring T cell function in the TME.46
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The ADME characteristics of immunomodulatory test compounds ICRT14, FH535,
salinomycin and other synthetic Wnt/β-catenin inhibitors were evaluated using
SwissADME. Though no in vivo pharmacokinetic data has been reported for ICRT14
or FH535, physiological characteristics predicted in silico can be utilized for the
anticipation of in vivo drug behavior. Their anticipated logP, TPSA values, and H-bond
acceptors and donors, relating to a drug’s ability to cross cellular membranes and
influence oral bioavailability, are similar to those of most orally bioactive drugs.47–49
Natural products, like salinomycin, are often exceptions to the algorithms used to predict
these properties; studying its pharmacokinetic properties with an in vivo model is
necessary for predicting its efficacy in humans.50 In contrast to in silico predictions,
salinomycin is capable of Pgp inhibition and reportedly metabolized by both CYP3A4
(major) and CYP2D6.51,52 Increased drug binding of CYPs and Pgp typically translates
to adverse drug reactions, increased generation of potentially toxic metabolites, and
decreased oral bioavailability or blood-brain barrier penetration as was indicated in the
in silico analysis of salinomycin.53 Contrasting toxicity reports of salinomycin in
animals and humans have been reported, but selective human studies have confirmed
the safety of injected salinomycin for targeting cancer stem cells providing a sufficient
therapeutic window for future studies.54,55 Though complex in comparison to those of
the synthetic inhibitors of this study, methods for synthesizing salinomycin and
potentially bioactive derivatives have been previously described.56,57 Notably,
construction of bispecific monoclonal antibodies using cell-specific antigens and
inhibiting Wnt-expression have demonstrated enhanced potency, requiring lower doses
for intended bioactivity which translates to improved in vivo tolerability.58,59 The
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comparatively low cost of small molecules, however, constitutes an attractive trait for
coadministration studies when considering the high costs associated with
immunotherapies.60 Exploration of Wnt/β-catenin inhibitors already being used in
clinical settings should be also considered due to their already established
pharmacokinetic profiles.17
In this study, an in vitro hMDSC model and in silico ADME analysis of various Wnt/βcatenin inhibitors were implemented to investigate the immunomodulatory effects of
small-molecule mediated Wnt-inhibition and facilitate the prediction of inhibitor in vivo
pharmacokinetics, respectively. Results from cell-based assays revealed cytotoxic drug
concentrations for T cells and hMDSCs as well as the potential of Wnt/β-catenin
inhibitors,

ICRT14

and

FH535,

for

modulating

hMDSC

production

of

CCL4/CCL17/IL-1β and IL-10 respectively. Considering the respective roles these
cytokines play in the TME, small molecule inhibition of Wnt/β-catenin represents an
interesting approach for improving the efficacy of immunotherapies. Translational ex
vivo or in vivo studies exploring the downstream effects of FH535-mediated inhibition
will be imperative for understanding the role of Wnt and PPAR signaling in
immunosuppressive MDSCs.
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Tables
Donor
1

Differentiation Method

Experiment(s)

+

Day 0: isolated CD3 T cells and stimulated
with 20 ng/mL IL-2; stimulated remaining
PBMCs with 5 μg/mL PGE-2, 500 ng/mL GMCSF, and 200 ng/mL IL-6

CellTiter-Glo 2.0 Cell Viability Assay
(Fig. 3a)

Day 4: restimulated 1 μg/mL PGE-2, 100
ng/mL GM-CSF, and 40 ng/mL IL-6

2-5

Day 5: harvested CD33+ hMDSCs
Same as above

✝

6

Same as above

✝

*(Stimulated with 50 ng/mL IFN-γ and 100
ng/mL LPS for hMDSC-activation and treated
with test compounds)
7

Same as above

8

*(Stimulated with 75 ng/mL IFN-γ and 150
ng/mL LPS for hMDSC-activation and treated
with test compounds)
Same as above

Proteomic comparisons (SWATH-MS)
Proteomic comparisons (SWATH-MS)

Multiplexed cytokine analysis (IL-10,
IL-12(p70), IL-13, IL-17A, IL-15,
CCL2, CCL4, CCL17, TNFα, IL-1β)
(Figs. 4 and S2)
✝
Proteomic comparisons (SWATH-MS)
Multiplexed cytokine analysis (IL-10,
TNFα, IL-1β, IL-8; MMP7, MMP9,
MPO) (Figs. 4 and S3)
CellTiter-Glo 2.0 Cell Viability Assay
(Fig. 3b-e)

*Day 0: 100 ng/mL GM-CSF, 100 ng/mL IL-6
Cytokine analysis (IL-10) (Fig. 4e)
*Day 4: 100 ng/mL IL-6

9

(Stimulated with 75 ng/mL IFN-γ and 150
ng/mL LPS for hMDSC-activation and treated
with test compounds)
Same as above

11

Same as above

CellTiter-Glo 2.0 Cell Viability Assay
(Fig. 3f, g)
Cytokine analysis (IL-10) (Fig. 4f)
✝
Proteomic comparisons (SWATH-MS)

*Variation in method
✝
Data not shown

Table 1. List of donors - their respective differentiation methods and experiments
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Physiochemical Properties
Compound Name

Formula

Molecular Weight

H-bond acceptors

H-bond donors

ICRT14

C21H17N3O2S

375.44

3

0

TPSA
80.5

ETC-159

C19H17N7O3

391.38

6

1

116.7

MSAB

C15H15NO4S

305.35

4

1

80.85

IWR-1

C25H19N3O3

409.44

4

1

79.37

CCT251545

C23H24ClN5O

421.92

3

1

63.05

FH535

C13H10Cl2N2O4S

361.2

4

1

100.37

Salinomycin

C42H70O11

751

11

4

161.21

Lipophilicity
Compound Name

iLOGP

WLOGP

XLOGP3

Consensus Log P

ICRT14

3.17

4.24

4.07

3.52

ETC-159

2.6

0.34

0.47

0.98

MSAB

2.7

3.47

2.64

2.61

IWR-1

3.28

3.23

2.93

3.11

CCT251545

3.17

3.15

2.89

3.07

FH535

1.88

4.9

3.89

2.86

Salinomycin

5.19

6.19

5.71

5

Water Solubility
Compound Name

Log S (ESOL)

Class (ESOL)

Log S (Ali)

Class (Ali)

Log S (Silicos-IT)

ICRT14

-5

Moderately soluble

-5.47

Moderately soluble

-6.25

Class (Silicos-IT)
Poorly soluble

ETC-159

-2.77

Soluble

-2.49

Soluble

-4.9

Moderately soluble

MSAB

-3.49

Soluble

-3.99

Soluble

-5.34

Moderately soluble

IWR-1

-4.34

Moderately soluble

-4.26

Moderately soluble

-6.34

Poorly soluble

CCT251545

-4.5

Moderately soluble

-3.87

Soluble

-7.46

Poorly soluble

FH535

-4.67

Moderately soluble

-5.7

Moderately soluble

-5.84

Moderately soluble

Salinomycin

-7.3

Poorly soluble

-8.86

Poorly soluble

-4.5

Moderately soluble

Drug Likeness
Compound Name

Lipinski

Ghose

Veber

Egan

Muegge

Bioavailability Score

ICRT14

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

0.55

ETC-159

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

0.55

MSAB

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

0.55

IWR-1

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

0.55

CCT251545

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

0.55

FH535

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

Yes; 0 violations

0.55

Salinomycin

No; 2 violations

No; 4 violations

No; 2 violations

No; 2 violations

No; 4 violations

0.11

Med Chem
Compound Name

PAINS

Brenk

Leadlikeness

Synthetic Accessibility

ICRT14

0 alerts

2 alerts

2

3.74

ETC-159

0 alerts

0 alerts

1

3.09

MSAB

0 alerts

0 alerts

0

2.44

IWR-1

0 alerts

2 alerts

1

4.01

CCT251545

0 alerts

0 alerts

1

3.97

FH535

0 alerts

2 alerts

2

2.71

Salinomycin

0 alerts

1 alert

3

9.77

Pharmacokinetics
Compound Name

GI absorption

BBB permeant

Pgp substrate

# CYPs inhibited

ICRT14

High

No

No

4

ETC-159

High

No

Yes

1

MSAB

High

No

No

3

IWR-1

High

No

No

5

CCT251545

High

Yes

Yes

3

FH535

High

No

No

4

Salinomycin

Low

No

No

1

Table 2. In silico analysis by SwissADME highlights physiologically advantageous
parameters of synthetic Wnt/β-catenin inhibitors versus the natural product
salinomycin.
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Figures

Figure 1. Theorized modulation of MDSC cytokine production via CD38
inhibition (78c). hMDSCs suppress cytotoxic T cells, such as those engineered in
CAR T-cell therapy, primarily through an upregulated secretion of IL-10. However,
cytokines such as CCL17, IL-17A, TGF-β, Arg1, etc. are also implicated in hMDSCmediated immunosuppression.3,5,6 Thus, small-molecule modulation of these
secretions may result in a less suppressive TME and support the success of
immunotherapies.
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Figure 2. Chemical structures of investigated Wnt/β-catenin pathway inhibitors.

109

Figure 3. Wnt/β inhibitors exhibit diverse cytotoxic effects on both T cells and
hMSDCs. Cells from Donor 1 were treated with (A) ICRT14 at 100, 10, 1, 0.1, 0.01,
0.001, 0.0001 μM (n = 4). (B) ETC-159, (C) MSAB, (D) IWR-1, and (E) CCT251545
110

were then tested on cells from Donor 8 at similar concentrations (n = 3). Finally, cells
from Donor 9 were treated with (F) FH535 and (G) salinomycin to measure cytotoxic
response in T cells and hMDSCs (n = 3). (H) Experimental IC50 values for all
compounds are also reported. A dashed line at 70% serves as a viability cutoff, thus
sample averages >70% are presumed to be healthy for the purpose of this study. Data
was plotted as mean values ± SD.
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Figure 4. Wnt/β-catenin inhibitors: ICRT14, salinomycin, and FH535
demonstrate modulation of key immunomodulatory cytokines in vitro. Data
shown includes results from two donors; hMDSCs from Donor 6 were investigated for
(A) CCL4, (B) CCL17, and (C) IL-1β signal in response to treatment with ICRT14 at
5 μM, 1 μM, and 0.1 μM in the presence of LPS (150 ng/mL) and IFN-γ (75 ng/mL),
demonstrating modulation of those cytokines (n = 4). (D) hMDSCs from the Donor 7
112

were tested again for IL-1β in response to treatment with ICRT14 at 5 μM and 1 μM,
showing no repeated reduction (n = 4). DMSO-treated (0.1%) hMDSCs, as well as
untreated cells, serve as control for this experiment. Data was plotted as mean values ±
SD and statistically significant results are indicated by P values analyzed by one-way
ANOVA analysis, * P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001.
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Supplementary Figures

Figure S1. Results from a preliminary ELISA assay measuring IL-10 production
in hMDSCs. (A) hMDSCs from Donor 4 were stimulated with 50 ng/mL IFN-γ and
simultaneously treated with Wnt/β-catenin inhibitor ICRT14 at 1 µM and 1-5 µM for 6
and 18 h, respectively. Pre-stimulation of hMDSCs with IFN-γ was insufficient for
inducing IL-10 production, thus any modulations of its signal were indiscernible.
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Figure S2. Results from multiplexed cytokine analysis of hMDSCs from Donor 6
after 24 h. Samples were measured for the production of various cytokines in
response to treatment with compound 78c at the marked concentrations in the presence
of LPS (150 ng/mL) and IFN-γ (75 ng/mL) (n = 4). Significant effects were observed
in modulation of (G) CCL4, (H) CCL17, and (J) IL-1β. Data was plotted as mean
values ± SD and statistically significant results are indicated by P values analyzed by
one-way ANOVA analysis, * P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001.
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Figure S3. Results from multiplexed cytokine analysis of hMDSCs from Donor 7
after 24 h. Samples were measured for the production of various cytokines in response
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to treatment with 78c at the marked concentrations, also in the presence of LPS and
IFN-γ (n = 4). DMSO-treated (0.1%) hMDSCs were used as vehicle samples and
untreated cells were used as controls. No dose-dependent cytokine modulation was
observed in this panel. Data was plotted as mean values ± SD and statistically significant
results are indicated by P values analyzed by one-way ANOVA analysis, * P ≤ 0.05 **
P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001.
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PERSPECTIVES
Taken into context with previous studies, the results of this research confirm that
the phenotypic characteristics of MDSCs are highly inducible, showing responsiveness
to cytokines and small molecules alike. By implementing the differentiation methods
described herein, MDSC-like cells can be generated from healthy donor blood and used
in subsequent experiments to translate and validate MDSC-specific targets identified by
SWATH-MS. Upon initial target validation, lead compounds should be further
evaluated for their safety and immunomodulatory influence on biosystems of increasing
complexity (e.g., in vivo). It is my hope that this research will provide a framework for
future studies seeking to evaluate the immunomodulatory potential of small molecules
on human MDSCs.
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